The Long-Term Effects of Postoperative Radiotherapy in Acromegaly: Results From a Single-Center Acromegaly Registry in Iran.
Najafipour. Farzad F; Jafarpour. Javad J; Bahrami. Amir A; Mobasseri. Majid M; Niafar. Mitra M; Najafipour. Mostafa M; Aliasgarzadeh. Akbar A; Aghamohammadzadeh. Naser N; Houshyar. Jalil J; Sadra. Vahideh V; Alamdari. Naimeh Mesri NM
Key Findings
- Radiotherapy gradually reduced GH from ~20 µg/L to ~2 µg/L over 10 years and IGF‑1 normalization rose from 5% to 60% over 15 years.
- High rates of late‑onset hypopituitarism: ~78% hypogonadism, 80% hypothyroidism, 82% hypocortisolism after 10 years.
- Small but notable neurological (4%) and visual (4%) complications were reported.
Practical Outcomes
- Radiation can lower IGF‑1 long‑term, but it comes with serious hormone loss and side effects, making it unsuitable as a DIY strategy. The study mainly reinforces that medical interventions for IGF‑1 reduction carry high risks and aren’t actionable for self‑directed health optimization.
Summary
This study looked at people with a rare hormone disorder called acromegaly who got radiation therapy after surgery. Over 10‑15 years, the treatment steadily lowered their growth hormone and IGF‑1 levels, but most ended up with new hormone deficiencies and some nerve or eye problems. For healthy folks, the findings don’t give a safe or practical way to tweak IGF‑1.
Abstract
Acromegaly is a rare but severe condition characterized by the excessive secretion of growth hormone (GH), leading to various metabolic alterations. Treatment options include surgery, pharmacotherapy, and radiotherapy (RT). RT can control the disease biochemically, either alone or in conjunction with medical therapy. This study aimed to evaluate the effectiveness of conventional RT in patients with postoperative acromegaly over a 15-year follow-up period, using specific cutoff criteria. A retrospective analysis was performed on 55 acromegaly patients who were monitored for an average of 15 (13.3-16.7) years and treated with conventional RT (median dose of 52 Gy) following pituitary surgery. Hormonal assessments included baseline and glucose-suppressed GH and IGF-1 levels, and side effects associated with RT were evaluated. The baseline GH level decreased from 20.7 (16-25.4) μg/L to 11.2 (8.3-14.1) μg/L (<i>p</i> < 0.001) at 2 years, further dropping to 5.8 (4.99-6.61) μg/L (<i>p</i> < 0.001) at 5 years, and to 2.2 (1.66-2.74) μg/L (<i>p</i> < 0.001) at 10 years after RT. Rates of patients achieving suppressed GH levels < 1 μg/L rose from 9% at 2 years to 25% at 5 years, 42% at 10 years, and 76% at 15 years. IGF-1 levels normalized in 5% of participants at 2 years, 14% at 5 years, 38% at 10 years, and 60% at 15 years. After 10 years, 78% of patients experienced hypogonadism, 80% experienced hypothyroidism, and 82% experienced hypocortisolism. Neurological complications were reported in 4% of patients 10 years post-RT, while 4% developed visual impairments and optic neuropathy within 5 years. The results suggest that conventional RT is an effective long-term management strategy for patients who do not respond adequately to medical therapy or surgery. However, the high incidence of late-onset hypopituitarism must be taken into account.
Study Information
pubmed
2025
2025-11-24T00:00:00.000Z
10.1155/ije/9945510
42